Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Short-term Investments (2022 - 2025)

Historic Short-term Investments for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q1 2025 value amounting to $1.0 million.

  • Indivior Pharmaceuticals' Short-term Investments fell 9878.05% to $1.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $1.0 million, marking a year-over-year decrease of 9878.05%. This contributed to the annual value of $1.0 million for FY2024, which is 9975.9% down from last year.
  • As of Q1 2025, Indivior Pharmaceuticals' Short-term Investments stood at $1.0 million, which was down 9878.05% from $1.0 million recorded in Q4 2024.
  • Over the past 5 years, Indivior Pharmaceuticals' Short-term Investments peaked at $415.0 million during Q4 2023, and registered a low of $1.0 million during Q4 2024.
  • Moreover, its 4-year median value for Short-term Investments was $82.0 million (2024), whereas its average is $103.8 million.
  • Per our database at Business Quant, Indivior Pharmaceuticals' Short-term Investments skyrocketed by 24873.95% in 2023 and then tumbled by 9975.9% in 2024.
  • Quarter analysis of 4 years shows Indivior Pharmaceuticals' Short-term Investments stood at $119.0 million in 2022, then surged by 248.74% to $415.0 million in 2023, then tumbled by 99.76% to $1.0 million in 2024, then changed by 0.0% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q1 2025, $1.0 million for Q4 2024, and $30.0 million during Q3 2024.